Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giulia Schiavoni
Institutions:
University of Rome Tor Vergata,
Instituto Nazionale Tumori Regina Elena
Observed institutions:
University of Rome Tor Vergata,
Istituti di Ricovero e Cura a Carattere Scientifico,
Instituto Nazionale Tumori Regina Elena
ORCID:
0009-0005-9975-0606
Observed ORCID:
0009-0005-9975-0606
OpenAlex ID:
A5001176826
Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer
2024
·
Giulia Schiavoni
, Beatrice Messina
, et al.
·
Journal of Translational Medicine
·
22
PDF
HER2 mutation as an emerging target in advanced breast cancer
2024
·
Giulia Bon
, Francesca Sofia Di Lisa
, et al.
·
Cancer Science
·
19
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024
·
Stefano Scalera
, Biagio Ricciuti
, et al.
·
Clinical Cancer Research
·
7
PDF
Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer
2026
·
Giulia Schiavoni
, Antonella Palmese
, et al.
·
Molecular Oncology
·
3
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
·
Clinical Cancer Research
·
1
Correction to: Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer
2024
·
Giulia Schiavoni
, Beatrice Messina
, et al.
·
Journal of Translational Medicine
·
1
Supplementary Table S1 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S9 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S11 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S16 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S8 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S15 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S6 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S3 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Table S2 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Table S3 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S1 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Table S4 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S13 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S18 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S4 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Table S6 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S2 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Data from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Supplementary Figure S7 from Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer
2026
·
Laura Cipriani
, Davide Mascolo
, et al.
Show more works
View as search
Works count:
64
Citation count:
53
H-index:
3
I10-index:
2
Year
Topic
Type